3- (formylhydroxyamino)- 2- (3- phenyl- 1- propyl)butanoic acid (2,2- dimethyl- 1- methylcarbamoyl- 1- propyl)amide

an ADAM10 inhibitor and antineoplastic agent; structure in first source

Also Known As:

GI 254023; GI-254023; GI254023; GI254023X

Networked: 12 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Amino Acids, Peptides, and Proteins: 1
- Peptides: 82426
  - Oligopeptides: 519
    - Dipeptides: 945
      - 3-(formylhydroxyamino)-2-(3-phenyl-1-propyl)butanoic acid (2,2-dimethyl-1-methylcarbamoyl-1-propyl)amide: 12
Organic Chemicals: 133
- Amines: 4871
  - Hydroxylamines: 16
    - Hydroxamic Acids: 239
      - 3-(formylhydroxyamino)-2-(3-phenyl-1-propyl)butanoic acid (2,2-dimethyl-1-methylcarbamoyl-1-propyl)amide: 12
- Carboxylic Acids: 973
  - Hydroxy Acids: 94
    - Hydroxamic Acids: 239
      - 3-(formylhydroxyamino)-2-(3-phenyl-1-propyl)butanoic acid (2,2-dimethyl-1-methylcarbamoyl-1-propyl)amide: 12

Experts

1.	Ludwig, Andreas: 2 articles (01/2019 - 01/2007)
2.	Chen, Chong: 2 articles (12/2015 - 08/2015)
3.	Xu, Kai-Lin: 2 articles (12/2015 - 08/2015)
4.	Hu, Ruimin: 1 article (01/2022)
5.	Liu, Aiguo: 1 article (01/2022)
6.	Nie, Dimin: 1 article (01/2022)
7.	Xi, Bixin: 1 article (01/2022)
8.	Xu, Hanxiao: 1 article (01/2022)
9.	Zhang, Yan: 1 article (01/2022)
10.	Brockhoff, Gero: 1 article (05/2021)

Related Diseases

1.	Neoplasms (Cancer) 05/18/2021 - "TMI-1 and GI254023X caused a reduced shedding of CX3CL1 and of HER2 in vitro but without effects on tumor cell proliferation or viability. " 10/16/2019 - "Primary HUVEC were irradiated with 2 or 4 Gy photons at a dose rate of 5 Gy/min. The permeability of an irradiated endothelial monolayer for macromolecules and tumor cells was analyzed in the presence or absence of the ADAM10/17 inhibitors GI254023X and GW280264X. " 01/01/2022 - "Interestingly, disintegrin and metalloproteinase domain-containing 10 (ADAM10) was upregulated in senescent tumor cells, and combined treatment with the ADAM10 inhibitor GI254023X and chemotherapeutic drugs inhibited MICA/B secretion and enhanced recognition and killing by NK cells. "
2.	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 08/01/2015 - "To investigate the effect of ADAM10 inhibitor GI254023X on the proliferation and apoptosis of acute T-lymphoblastic leukemia Jurkat cells and its mechanisms. " 08/01/2015 - "[Effect of ADAM10 Inhibitor GI254023X on Proliferation and Apoptosis of Acute T-Lymphoblastic Leukemia Jurkat Cells In Vitro and Its Possible Mechanisms]."
3.	Ganglion Cysts (Ganglion) 04/01/2013 - "N-cadherin ectodomain shedding was apparent in control cultures after 24 h, when ganglion cell differentiation was observed, but ADAM10 siRNA and GI254023X treatment inhibited these processes. "
4.	Multiple Myeloma 12/01/2015 - "To investigate the effect of ADAM10 inhibitor GI254023X on the proliferation and apoptosis of multiple myeloma H929 cell line and its mechanisms. " 12/01/2015 - "[Effect of ADAM10 Inhibitor GI254023X on Proliferation and Apoptosis of Multiple Myeloma H929 Cells and Its Possible Mechanisms]."
5.	Mesothelioma 01/01/2019 - "We show, in vitro, that ADAM10 targeting through shRNA and pharmacological (GI254023X) approaches reduced drastically mesothelioma cell migration and invasion, as well as for human mesothelioma cells treated with siRNA targeting ADAM10. "

Related Drugs and Biologics

1.	Metalloproteases (Metalloproteinases)
2.	Small Interfering RNA (siRNA)
3.	Disintegrins
4.	Cadherins (E-Cadherin)
5.	Proteins (Proteins, Gene)
6.	GW280264X
7.	apratastat
8.	cadherin 5
9.	mica

Related Therapies and Procedures

1.	Ligation